Line Bjørge

Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk

Ganna Chornokur, Hui‐Yi Lin, Jonathan P. Tyrer et al. · PLoS ONE · 2015 · 901 citations · Full text

Landscape of genomic alterations in cervical carcinomas

Akinyemi I. Ojesina, Lee Lichtenstein, Samuel S. Freeman et al. · Nature · 2013 · 866 citations · Full text

Cervical Cancer, Pathology, Cancer Genomics +4

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Mansoor Raza Mirza, Elisabeth Åvall Lundqvist, Michael J. Birrer et al. · The Lancet Oncology · 2019 · 239 citations

Superiority Trial, Medicine, Gynecology +8

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Andreas du Bois, Gunnar B. Kristensen, Isabelle Ray‐Coquard et al. · The Lancet Oncology · 2015 · 207 citations · Full text

Placebo-controlled Phase 3, Medicine, Metronomic Therapy +9

The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis

William J. Gibson, Erling A. Høivik, Mari K. Halle et al. · Nature Genetics · 2016 · 201 citations · Full text

Oncology, Tumor Heterogeneity, Genomic Landscape +8